VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
Vistakon, Division of Johnson & Johnson Vision Car · Decision date Dec 20, 2005
What did the FDA approve?
FDA approved the Vistakon senofilcon A contact lens platform on December 20, 2005. The approval covers spherical, multifocal, toric, and multifocal-toric designs for refractive ametropia in phakic or aphakic persons with non-diseased eyes, with astigmatism limits of 1.00D or less for spherical, 0.75D or less for multifocal, and 10.00D or less for toric and multifocal-toric lenses.
The lenses may be prescribed for single-use disposable wear or frequent/planned replacement wear using chemical disinfection only. Daily wear and extended wear up to 6 nights/7 days of continuous wear are permitted, with an initial daily wear evaluation recommended before gradual introduction of extended wear. The UV blocking feature is described as helping protect against transmission of harmful UV radiation to the cornea and into the eye.
FDA approval order statement
APPROVAL FOR THE VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER. THE DEVICE IS INDICATED FOR USE AS FOLLOWS: THE VISTAKON (SENOFILCON A) SOFT CONTACT LENS (SPHERICAL) IS INDICATED FOR THE OPTICAL CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO HAVE 1.00D OR LESS OF ASTIGMATISM. THE VISTAKON (SENOFILCON A) MULTIFOCAL SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF DISTANCE AND NEAR VISION IN PRESBYOPIC, PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO MAY HAVE 0.75D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) TORIC SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF VISUAL ACUITY IN PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES THAT ARE HYPEROPIC OR MYOPIC AND MAY HAVE 10.00D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) MULTIFOCAL-TORIC SOFT CONTACT LENS IS INDICATED FOR THE OPTICAL CORRECTION OF DISTANCE AND NEAR IN PRESBYOPIC PHAKIC OR APHAKIC PERSONS WITH NON-DISEASED EYES WHO MAY HAVE 10.00D OF ASTIGMATISM OR LESS. THE VISTAKON (SENOFILCON A) UV BLOCKING SOFT CONTACT LENS HELP PROTECT AGAINST TRANSMISSION OF HARMFUL UV RADIATION TO THE CORNEA AND INTO THE EYE. EYE CARE PROFESSIONALS MAY PRESCRIBE THE LENSES EITHER FOR SINGLE-USE DISPOSABLE WEAR OR FREQUENT/PLANNED REPLACEMENT WEAR WITH CLEANING, DISINFECTION AND SCHEDULED REPLACEMENT. WHEN PRESCRIBED FOR FREQUENT/PLANNED REPLACEMENT WEAR THE LENSES MAY BE CLEANED AND DISINFECTED USING A CHEMICAL DISINFECTION SYSTEM ONLY. VISTAKON (SENOFILCON A) CONTACT LENSES MAY BE PRESCRIBED FOR DAILY WEAR AND EXTENDED WEAR FOR UP TO 6 NIGHTS/7 DAYS OF CONTINUOUS WEAR. IT IS RECOMMENDED THAT THE CONTACT LENS WEARER FIRST BE EVALUATED ON A DAILY WEAR SCHEDULE. IF SUCCESSFUL, THEN A GRADUAL INTRODUCTION OF EXTENDED WEAR CAN BE FOLLOWED AS DETERMINED BY THE PRESCRIBING EYE CARE PROFESSIONAL.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Dec 20, 2005
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P040045
- Regulatory pathway
- Premarket approval application
- Product code
- LPM
- Decision code
- APPR
- Decision date
- Dec 20, 2005
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lenses, soft contact, extended wear.
- Product code
- LPM
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P040045 received
Application receipt date recorded by FDA.
P040045 · FDA decision
APPR
P040045/S145 · Related supplement
VISTAKON (SENOFILCON A) CONTACT LENS, CLEAR AND VISIBILITY TINTED WITH UV BLOCKER
P040045/S146 · Related supplement
VISTAKON (SENOFILCON A) Brand Contact Lenses
P040045/S147 · Related supplement
VISTAKON (senofilcon A) Brand Contact Lenses
Timeline entries are records held by MedtechLedger for P040045. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040045
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Sep 2, 2026 | FDA | |
VISTAKON (SENOFILCON A) Brand Contact LensesP040045/S146 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 8, 2026 | FDA |
VISTAKON (senofilcon A) Brand Contact LensesP040045/S147 | Vistakon, Division of Johnson & Johnson Vision Car | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code LPM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bausch + Lomb Ultra (samfilcon A) Contact LensesP170035/S021 | Bausch and Lomb, Inc., | PMA supplement | Sep 14, 2026 | FDA |
BIOFINITY (COMFILCON A)P080011/S204 | CooperVision, Inc. | PMA supplement | Sep 2, 2026 | FDA |
| Bausch and Lomb, Inc., | PMA approval | Apr 30, 2018 | FDA | |
BIOFINITY (COMFILCON A)P080011 | CooperVision, Inc. | PMA approval | Nov 19, 2008 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vistakon, Division of Johnson & Johnson Vision Car
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 7500 Centurion Pkwy., Suite 100 - Erca, Jacksonville, FL, 32256
Sources and methodology
- Original FDA record: P040045
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


